info@RegenProtocols.com
561-325-7000
141 NW 20th St., Suite G1 Boca Raton, FL 33431
My Regen Protocols logo
Contact Us
My Regen Protocols logo
Contact Us

Orthopedic Repair & Joint Regeneration Protocol

Summary

A structured regenerative framework for cartilage preservation, tendon and ligament repair, and long-term joint integrity in degenerative joint disease.

Overview

A structured regenerative framework designed to support cartilage preservation, tendon and ligament repair, and long-term joint integrity. The protocol combines angiogenic peptides, cellular migration enhancers, and chondroprotective compounds to address osteoarthritis, soft tissue degeneration, and structural joint damage.

The goal is sustained tissue remodeling, better biomechanical stability, and less progressive degeneration.

Clinical scope

  • Osteoarthritis (mild to moderate)
  • Tendon and ligament injury
  • Cartilage degeneration
  • Bone fracture recovery support
  • Joint preservation and structural support

Core stack

AgentRouteDoseFrequencyDuration
BPC-157Subcutaneous (SubQ), periarticular500 mcgTwice daily8–12 weeks
TB-500 (thymosin β4)SubQ1.5–2.0 mgTwice weekly (loading), then weekly (maintenance)10–12 weeks
AOD-9604SubQ or intra-articular (if appropriately trained)300–600 mcgDaily12 weeks

Enhanced stack (advanced degeneration, multi-joint involvement, or prolonged remodeling support)

AgentRouteDoseFrequencyDuration
GHK-CuSubQ1–3 mgDaily8–12 weeks
CJC-1295 / IpamorelinSubQ100 mcg / 100 mcgOnce daily (evening)12–16 weeks

Phase structure

1

Phase 1: Structural stabilizationWeeks 1–4

  • BPC-157 twice daily, periarticular
  • TB-500 twice weekly (loading)
  • AOD-9604 daily
2

Phase 2: Active regenerationWeeks 5–8

  • Maintain BPC-157
  • Move TB-500 to weekly
  • Continue AOD-9604
  • Add GHK-Cu if the enhanced stack is indicated
3

Phase 3: Remodeling and consolidationWeeks 9–12+

  • Continue AOD-9604 through Week 12
  • Taper BPC-157 if structural stability is achieved
  • Maintain GH secretagogues if extended remodeling is required

Joint-specific considerations

Knee (osteoarthritis)

  • Periarticular SubQ around the joint line
  • AOD-9604 intra-articularly if properly trained
  • Consider a bilateral protocol when indicated
  • Space intra-articular injections 2–4 weeks apart

Shoulder (rotator cuff)

  • SubQ near the supraspinatus insertion
  • Combine with structured physical therapy
  • BPC-157 is particularly effective for tendon-to-bone healing

Lumbar spine (disc)

  • Paraspinal SubQ at the affected level
  • Systemic SubQ if a localized injection is not feasible
  • Consider adding sleep-support peptides if pain disrupts recovery

Hip (labral injury or osteoarthritis)

  • Peritrochanteric SubQ
  • Extended duration (12–16 weeks)
  • AOD-9604 is critical for cartilage preservation

Elbow (epicondylitis)

  • SubQ near the lateral epicondyle
  • BPC-157 plus TB-500 is often sufficient
  • A duration of 6–8 weeks is common

Achilles tendon and plantar fascia

  • SubQ along the tendon or fascia
  • BPC-157 is highly effective
  • Add TB-500 for enhanced cellular migration if needed

Rationale

AOD-9604 is the central chondroprotective component, supporting cartilage preservation and structural regeneration. BPC-157 increases growth factor receptor expression in tendon and ligament tissue, while TB-500 helps cells migrate into damaged structures. Together, these compounds form a synergistic triad for orthopedic repair.

GHK-Cu supports collagen remodeling and restoration of the extracellular matrix. CJC-1295/Ipamorelin raise systemic growth hormone and IGF-1, which supports sustained tissue remodeling over longer treatment durations.

Expected outcomes

  • Improved joint mobility and function
  • Reduced inflammatory joint pain
  • Enhanced cartilage resilience
  • Accelerated tendon and ligament healing
  • Long-term structural stabilization

Monitoring

  • Range of motion assessment
  • Functional performance metrics
  • WOMAC or joint-specific scoring when appropriate
  • Inflammatory markers if clinically indicated
  • IGF-1 monitoring if GH secretagogues are used

Contraindications

  • Active malignancy
  • Pregnancy or breastfeeding
  • Active systemic infection
  • Uncontrolled endocrine disorders
  • Hypersensitivity to any component
Clinical disclaimer. This protocol is provided for informational and educational purposes for licensed healthcare professionals. These compounds and strategies are not intended to diagnose, treat, cure, or prevent any disease. The statements have not been evaluated by the Food and Drug Administration. Clinical evaluation and patient-specific judgment are required before implementation.
Picture of Bruce Bertman, CEO of Networld Online, Inc.

Bruce Bertman, CEO of Networld Online, Inc.

Bruce Bertman, CEO of Networld Online, Inc., is a distinguished marketing professional with a career spanning work with AT&T, IBM, Inacomp Computer Centers, and numerous charitable organizations. Based in Boca Raton, Florida, he is a respected digital marketing leader and visionary who empowers clients and partners to succeed. As a business innovator and speaker, Bertman launched three companies and guided hundreds of clients to sales success.
Facebook
Twitter
Email
Print

Related protocols

TEST Protocol QA 2

Open protocol

TEST – Protocol QA

Open protocol

Neuro-Restorative Cognitive Protocol

A two-phase neuro-restorative approach to age-related cognitive decline and executive dysfunction that pairs peptides with cognitive behavioral therapy.
Open protocol

Related article

Load More